BUY Glenmark Pharmaceuticals — Arun Kumar Mantri, 23 Sept 2026

byArun Kumar MantriHorizon: Swing (≤2wk)23 Sept 2026via CNBC Awaaz.

Entry₹2,474Inferred

Target₹2,540

Stop loss₹2,445-1.17% risk

CMP₹2,4753h ago

Active+0.04%+2.63%upside left 14d left

Follow Arun Kumar Mantri for new calls(26% target hit, 164 closed calls)Get alerts Watch GLENMARK for new buy/sell callsGet alerts See 254 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 23 Sept, 7:51 pm IST

9 supporting1 neutral1 opposing

Supports the BUY call (9)

Glenmark Pharmaceuticals' Goa facility received an Establishment Inspection Report (EIS) from the U.S. FDA with a Voluntary Action Indicated (VAI) classification, suggesting no major compliance issues

BSE · Company Update·23 Sept · today

2 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·23 Sept · today

Glenmark Pharmaceuticals Ltd spurts 0.5%, gains for fifth straight session

NewsGoogle News·22 Sept · yesterday

Pharma Stocks Rally: BSE Healthcare index hits new high, Sun Pharma, Torrent Pharma, Glenmark gain up to 5%

NewsGoogle News·21 Sept · 2d ago

Glenmark Pharma's biotech arm IGI unveils ISB 2301 to target solid tumors

NewsGoogle News·20 Sept · 3d ago

Neutral / worth noting (1)

Glenmark transfers nebulizer brands to subsidiary for ₹223 Cr

NewsGoogle News·23 Sept · today

Weighs against the BUY call (1)

MACD below its signal line — bearish momentum

Technicals · macd·23 Sept · today

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.